Quantifying the fatal and non-fatal burden of disease associated with child growth failure, 2000–2023: a systematic analysis from the Global Burden of Disease Study 2023Show others and affiliations
Number of Authors: 4212026 (English)In: The Lancet Child and Adolescent Health, ISSN 2352-4642, E-ISSN 2352-4650, Vol. 10, no 1, p. 22-38Article in journal (Refereed) Published
Abstract [en]
Background Child growth failure (CGF), which includes underweight, wasting, and stunting, is among the factorsmost strongly associated with mortality and morbidity in children younger than 5 years worldwide. Poor height andbodyweight gain arise from a variety of biological and sociodemographic factors and are associated with increasedvulnerability to infectious diseases. We used data from the Global Burden of Diseases, Injuries, and Risk FactorsStudy (GBD) 2023 to estimate CGF prevalence, the risk of infectious diseases associated with CGF, and the diseasemortality, morbidity, and overall burden associated with CGF.
Methods In this analysis we estimated the all-cause and cause-specific (diarrhoea, lower respiratory tract infections,malaria, and measles) disability-adjusted life-years (DALYs) lost and mortality associated with stunting, wasting,underweight, and CGF in aggregate. We combined the burden associated with mild, moderate, and severe forms ofCGF: stunting was defined as height-for-age Z scores (HAZ) less than –1, underweight was defined as weight-for-ageZ scores (WAZ) less than –1, and wasting was defined as weight-for-height Z scores (WHZ) less than –1, according toWHO Child Growth Standards. Population-level continuous distributions of HAZ, WAZ, and WHZ were estimatedfor 2000 to 2023 using data from surveys, literature, and individual-level study data. The risk of incidence of, andmortality due to, diarrhoea, lower respiratory infections, malaria, and measles was separately estimated in a metaregressionframework from longitudinal cohort data for Z scores less than –1. Finally, fatal outcomes associated withthese diseases were estimated with vital registration, verbal autopsy, and case-fatality data, while non-fatal outcomeswere estimated with surveys as well as health-care utilisation and case reporting data. The exposure prevalence andrelative risk estimates were from continuous distributions, allowing for direct assessment of the attributable fractionsfor mild, moderate, and severe stunting, underweight, wasting, and the combined impact of child growth failurewithin populations. All estimates were age-specific, sex-specific, geography-specific, and year-specific.
Findings We estimated that, in children younger than 5 years in 2023, CGF was associated with 79·4 million(95% uncertainty interval [UI] 47·0–106) DALYs lost and 880 000 (517 000–1 170 000) deaths. This represented17·9% (10·6–23·8) of 444 million (434–457) total under-5 DALYs and 18·8% (11·1–25·0) of all 4·67 million(4·59–4·75) under-5 deaths. Compared to stunting (33·0 million [24·1–42·2] DALYs, 373 000 [272 000–477 000]deaths) and wasting (39·2 million [23·8–53·0] DALYs, 428 000 [256 000–583 000] deaths), childhood underweight wasassociated with the largest share of CGF-related disease burden: 52·2 million (21·9–75·1) DALYs and 573 000(236 000–824 000) deaths in children younger than 5 years in 2023.
Interpretation CGF remains a leading factor associated with death and disability in children younger than 5 years,despite global attention and focused interventions to reduce the prevalence of associated CGF indicators. Our findingsunderscore the need for policies, strategies, and interventions that focus on all indicators of CGF to reduce itsassociated health burden.
Place, publisher, year, edition, pages
Elsevier , 2026. Vol. 10, no 1, p. 22-38
National Category
Public Health, Global Health and Social Medicine
Research subject
Health-Promoting Work
Identifiers
URN: urn:nbn:se:hig:diva-48991DOI: 10.1016/s2352-4642(25)00303-7PubMedID: 41344792OAI: oai:DiVA.org:hig-48991DiVA, id: diva2:2020656
Funder
Bill and Melinda Gates Foundation2025-12-112025-12-112026-01-15Bibliographically approved